Cyclo-oxygenase 2 Inhibitors Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 20+ Companies Working in the Domain
23 sept. 2024 11h30 HE
|
DelveInsight Business Research LLP
New York, USA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cyclo-oxygenase 2 Inhibitors Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 20+ Companies...
UN Global Compact and Tsao Pao Chee Forge Alliance to Revolutionize Higher Education for a Sustainable Future
19 sept. 2024 18h00 HE
|
United Nations Global Compact
New York, United States of America, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The UN Global Compact, through its Principles for Responsible Management Education (PRME) initiative, has partnered with Octave...
Heramba Electric's Kiepe Electric Subsidiary Receives Order for SmartHybrid Battery Drive for Center-Cab Locomotive DE 18 from Vossloh Rolling Stock
19 sept. 2024 08h30 HE
|
Heramba Electric plc
KIEPE equips Vossloh Rolling Stock's DE 18 center-cab locomotives with SmartHybrid battery power converters; eleven systems have already been delivered System integration by KIEPE replaces the...
ImCheck Receives FDA Fast Track Designation for ICT01 in Combination with Azacitidine and Venetoclax in First-Line Acute Myeloid Leukemia for Patients Unfit for Induction Chemotherapy Treatment
18 sept. 2024 05h00 HE
|
ImCheck Therapeutics SAS
ImCheck Receives FDA Fast Track Designation for ICT01in Combination with Azacitidine and Venetoclaxin First-Line Acute Myeloid Leukemiafor Patients Unfit for Induction Chemotherapy Treatment ICT01,...
Heramba Electric's Kiepe Electric Subsidiary to Supply Traction Inverters for LOHR & SNCF's DRAISY Project Providing Revolutionary Very Light Train for the Region
16 sept. 2024 09h00 HE
|
Heramba Electric plc
100% battery-powered light train DRAISY is intended to give new impulse to rural railway lines KIEPE provides the traction package for DRAISY with the Kiepe Traction Inverter (KTI) including the...
Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European Society for Medical Oncology (ESMO) Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors
14 sept. 2024 03h00 HE
|
Avacta Group
This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act...
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
14 sept. 2024 03h00 HE
|
Immunocore Holdings plc
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically active as monotherapy and in combination with...
Hybrid Exchange GRVT Secures 16 Top Market Makers and $3.3B Monthly Volume Ahead of Q4 Mainnet Launch
13 sept. 2024 10h50 HE
|
GRVT Technologies Pte Ltd
SINGAPORE, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Hybrid cryptocurrency exchange GRVT (pronounced “gravity”), ZKsync’s first official Validium ZK Chain, is thrilled to announce its partnership with 16...
CD47 Inhibitor Drug Clinical Trials Market Outlook to 2028 - Emerging CD47 Inhibitor Clinical Trials Showcase Potential Cancer Treatment Breakthroughs
06 sept. 2024 06h48 HE
|
Research and Markets
Dublin, Sept. 06, 2024 (GLOBE NEWSWIRE) -- The "Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028" report has been added to ResearchAndMarkets.com's offering....
Immuron Plans Phase 2 Trial for IMM-529 following FDA review
05 sept. 2024 11h54 HE
|
Immuron Limited
Key Points Immuron completes pre-IND meeting with FDA on the development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI)Previous clinical trial data on...